Tracers / [11C]PD153035
[11C]PD153035
Also written as C-11 PD153035; C-11-PD153035; PD153035
- Radionuclide
- C-11 t½ 20.36 min
- Modality
- PET
- Production route
- —
- Stage
- investigational (evaluated in patients, pilot clinical studies)
- Syntheses indexed
- 1
What it is
- Compound class
- 4-anilinoquinazoline, ATP-competitive EGFR tyrosine kinase inhibitor
- Target / mechanism
- Epidermal growth factor receptor (EGFR) tyrosine kinase domain PMID 35455447
- Clinical application
- Non-small cell lung cancer patients treated with EGFR-TKI (erlotinib), for predicting sensitivity/response and survival outcomes PMID 21903741
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 17624262 2007 Chin Med J (Engl) Synthesis of (11)C-PD153035 was performed in the Tracerlab FXc system. |
Need this precursor?We can point you to suppliers for [11C]PD153035, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [11C]PD153035.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with C-11.